Literature DB >> 18036791

Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer--the CHHiP trial.

V S Khoo, D P Dearnaley.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 18036791     DOI： 10.1016/j.clon.2007.10.008

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN： 0936-6555            Impact factor:   4.126


× No keyword cloud information.
  13 in total

1.  The effect of 6 and 15 MV on intensity-modulated radiation therapy prostate cancer treatment: plan evaluation, tumour control probability and normal tissue complication probability analysis, and the theoretical risk of secondary induced malignancies.

Authors:  M Hussein; S Aldridge; T Guerrero Urbano; A Nisbet
Journal:  Br J Radiol       Date:  2011-10-18       Impact factor: 3.039

2.  Image-guided radiotherapy of the prostate using daily CBCT: the feasibility and likely benefit of implementing a margin reduction.

Authors:  I F Maund; R J Benson; J Fairfoul; J Cook; R Huddart; A Poynter
Journal:  Br J Radiol       Date:  2014-10-29       Impact factor: 3.039

Review 3.  Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?

Authors:  Ivan R Vogelius; Søren M Bentzen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-30       Impact factor: 7.038

4.  The value of image-guided intensity-modulated radiotherapy in challenging clinical settings.

Authors:  S J Treece; M Mukesh; Y L Rimmer; S J Tudor; J C Dean; R J Benson; D L Gregory; G Horan; S J Jefferies; S G Russell; M V Williams; C B Wilson; N G Burnet
Journal:  Br J Radiol       Date:  2013-01       Impact factor: 3.039

5.  Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer.

Authors:  Mark Ritter
Journal:  Semin Radiat Oncol       Date:  2008-10       Impact factor: 5.934

6.  Hypofractionation for prostate cancer.

Authors:  Mark Ritter; Jeffrey Forman; Patrick Kupelian; Colleen Lawton; Daniel Petereit
Journal:  Cancer J       Date:  2009 Jan-Feb       Impact factor: 3.360

7.  Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up.

Authors:  A Creak; E Hall; A Horwich; R Eeles; V Khoo; R Huddart; C Parker; C Griffin; M Bidmead; J Warrington; D Dearnaley
Journal:  Br J Cancer       Date:  2013-07-23       Impact factor: 7.640

Review 8.  Exploiting biological and physical determinants of radiotherapy toxicity to individualize treatment.

Authors:  J E Scaife; G C Barnett; D J Noble; R Jena; S J Thomas; C M L West; N G Burnet
Journal:  Br J Radiol       Date:  2015-05-26       Impact factor: 3.039

9.  Accumulated dose to the rectum, measured using dose-volume histograms and dose-surface maps, is different from planned dose in all patients treated with radiotherapy for prostate cancer.

Authors:  Jessica E Scaife; Simon J Thomas; Karl Harrison; Marina Romanchikova; Michael P F Sutcliffe; Julia R Forman; Amy M Bates; Raj Jena; M Andrew Parker; Neil G Burnet
Journal:  Br J Radiol       Date:  2015-07-24       Impact factor: 3.039

10.  Risk-adaptive volumetric modulated arc therapy using biological objective functions for subvolume boosting in radiotherapy.

Authors:  Nicholas Hardcastle; Wolfgang A Tome
Journal:  Comput Math Methods Med       Date:  2012-06-27       Impact factor: 2.238
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.